- Home
- SPHR vs VKTX Comparison
SPHR vs VKTX Comparison
Compare SPHR & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPHR | VKTX |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.0B |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SPHR | VKTX |
|---|---|---|
| Price | $138.57 | $36.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $116.18 | $95.86 |
| AVG Volume (30 Days) | 479.6K | ★ 5.3M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 113.03 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,220,045,000.00 | N/A |
| Revenue This Year | $12.70 | N/A |
| Revenue Next Year | $2.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.81 | N/A |
| 52 Week Low | $57.01 | $25.04 |
| 52 Week High | $181.63 | $43.15 |
Technical Indicators
Market Signals| Indicator | SPHR | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.33 | 55.55 |
| Support Level | $132.73 | $29.26 |
| Resistance Level | $148.98 | $42.79 |
| Average True Range (ATR) | 5.46 | 2.16 |
| MACD | -0.30 | 0.79 |
| Stochastic Oscillator | 26.72 | 52.99 |
Price Performance
Historical ComparisonAbout SPHR Sphere Entertainment Co.
Sphere Entertainment Co is a live entertainment and media company. The firm creates, writes, casts, produces, and tours shows and events. The group has two reportable segments: Sphere and MSG Networks. Sphere is a next-generation entertainment medium, and MSG Networks operates two regional sports and entertainment networks, as well as a direct-to-consumer (DTC) and authenticated streaming product.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.